

NWR Virtual Healthcare Investor Conference Presentation

Microba Life Sciences Limited (ASX: MAP) (“Microba”), is pleased to announce that it will present at the NWR Virtual Healthcare Investor Conference today, Tuesday 21 March 2023, at 10:20am AEDT (Sydney/Melbourne) / 9:20am (Brisbane).

CEO, Dr Luke Reid and **Senior Vice President of Therapeutics, Prof Trent Munro** will deliver the presentation.

A copy of the presentation is attached to this announcement.

Shareholders, investors and interested parties are encouraged to register to attend the presentation at the following link:

https://us02web.zoom.us/webinar/register/WN_NuxbhE1qT46ALFRH9SCoaA

A recording will be available at the above link shortly after the conclusion of the live session, and the replay will also be available via the Company’s website and social media channels.

Questions can be submitted in advance of the presentation to matt@nwrcommunications.com.au

For more information please visit: <https://nwrcommunications.com/healthconf>

This announcement has been authorised for release by the Chairman and Chief Executive Officer.

For further information, please contact:

Dr Luke Reid

Chief Executive Officer

E: Luke.Reid@microba.com

Simon Hinsley

Investor / Media Relations

E: simon@nwrcommunications.com.au

T: +61 401 809 653

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

For more information visit: www.microba.com

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.

MICROBA™

Transforming health through the human microbiome

21 March 2023 | *Authorised for release by the CEO & Chairman*

Disclaimer

This presentation (**Presentation**) has been prepared by Microba Life Sciences Limited (**Microba**).

Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of release of this Presentation. Microba may in its absolute discretion, but without being under any obligation to do so, update or supplement this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Microba or that would be required in a prospectus or other disclosure document prepared in accordance with the requirements of the *Corporations Act 2001* (Cth) (**Corporations Act**).

Industry and market data – In this Presentation, Microba refers to certain market, industry, and statistical data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither Microba nor its representatives have independently verified any such data and no representation or warranty, express or implied, is made as to its fairness, accuracy, correctness, completeness or adequacy. Some data is also based on the good faith estimates of Microba, which are derived its reviews of internal sources as well as the independent sources described above.

Not an offer - This Presentation is not a prospectus or other disclosure document under the Corporations Act and will not be lodged with the Australian Securities and Investments Commission. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this Presentation (including electronically) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions and should seek your own advice. Any non-compliance with these restrictions may contravene applicable securities laws.

Not investment or medical advice - The information contained in this Presentation is not investment, financial product advice, medical advice or any medical recommendation or recommendation to acquire Shares. This Presentation has been prepared without taking into account your investment objectives, financial situation, medical or any other particular needs. This Presentation does not and will not form any part of any contract for the acquisition of shares. Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation. Before making an investment decision, you should consider whether it is a suitable investment for you in light of your own investment objectives, financial situation and particular needs and having regard to the merits or risks involved. Independent financial advice is recommended.


Future performance - This Presentation contains forward looking statements. Forward-looking statements generally relate to current expectations, hopes, beliefs, intentions, strategies or productions about future events or Microba's future financial or operating performance. For example, statements regarding anticipated growth in the industry in which Microba operates and anticipated growth in demand for Microba's products and services, projections of Microba's future financial results and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "pro forma", "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance and may involve known and unknown risks, uncertainties and other factors, many of which are outside the control of Microba. You are cautioned not to place undue reliance on any forward looking statement. Forward looking statements in this Presentation are based on assumptions and contingencies which are subject to change without notice. Actual results, performance or achievements may vary materially from any forward looking statements and the assumptions on which statements are based. The forward looking statements in this Presentation are based on information available to Microba as at the date of this Presentation and nothing in this Presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Except as required by law or regulation, Microba undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise.

Financial data – All dollar values in Australian dollars (A\$ or \$) unless otherwise stated. Recipients should note that this Presentation contains historical and pro-forma financial information. Any financial information provided in this Presentation is for illustrative purposes only and is not represented as being indicative of Microba's views on its future financial condition and/or performance.

Trademarks – This Presentation may contain trademarks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, trade names and copyrights referred to in this Presentation may be listed without the © or ® symbols, but Microba asserts, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, trade names and copyright.

Disclaimer - Except for any statutory liability which cannot be excluded, Microba, its related bodies corporate and their respective officers, employees and advisers expressly disclaim all liability (including negligence) for any direct or indirect loss or damage which may be suffered by any person in relation to, and take no responsibility for, any information in this Presentation or any error or omission therefrom, and make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of this Presentation.

Two core business segments driven by a proprietary databank



Company Snapshot



Continuous YoY revenue growth over 5 years of operations



Partnerships with market leaders incl. **SYNLAB** (GR:SYAB), **Sonic Healthcare** (ASX: SHL), **Genova Diagnostics**, and **G42**



Large, unique, proprietary microbiome databank



3 key therapeutic programs with lead IBD drug candidate **progressing to Phase 1 trial**



World-leading technology in the emerging **US\$4.89 billion** microbiome sector¹



Globally **leading microbiome expertise** complemented by drug discovery experts including Prof. Ian Frazer

Recent Milestones



STRATEGIC INVESTMENT & PARTNERSHIP

Sonic acquired a 19.99% stake in Microba and entered into a distribution partnership for 7 countries.



EXPANSION INTO ITALY, PORTUGAL, CZECH REPUBLIC & TÜRKIYE

Signed, commenced and first sales achieved in Italy, Portugal and Türkiye.



NEXT GENERATION HEALTHCARE TESTING LAUNCHED

New MetaXplore™ test range launched to healthcare professionals.



MANUFACTURING THROUGH TO DRUG PRODUCT FOR IBD PROGRAM

Lead drug candidate MAP 315, engineering production through to full encapsulated drug product.



FIRST POSTIVE ANIMAL DATA FOR CANCER PROGRAM

A significant reduction in tumour size was observed for Microba's therapeutic leads in a mouse model of melanoma



FDA PRE-IND MEETING POSITIVE OUTCOME

Positive formal feedback from the FDA on Pre-IND briefing book and pre-clinical package.

Microbiome Services

Driving global revenues
and data growth

**World-leading
microbiome analysis
technology** unlocks
routine testing and
microbiome therapies

up to **95%**
coverage¹

up to **34x**
more accurate²

Other
Technology

Microba
Technology



THE UNIVERSITY
OF QUEENSLAND
AUSTRALIA

Published in
 **frontiers**
in Microbiology

MICROBA

¹ Calculated by analysing more than 10k samples across Microba's databank
² Microba achieves 6-34x lower false discovery rate than academic competitors
Parks, Donovan H., et al. "Evaluation of the Microba Community Profiler for Taxonomic Profiling of Metagenomic Datasets From the Human Gut Microbiome." *Frontiers in microbiology* 12 (2021).

*Illustrative visualisation of the gastrointestinal tract and the additional
bacteria visible to Microba with its platform technology*

This graphic is for illustrative purposes only

Next Generation microbiome testing product range launched in Australia to healthcare professionals



- Large addressable market
 - >30% of the population suffer from a disorder of gut-brain interaction (DGBI) related to the bowel¹
 - >20% of the population is estimated to suffer from a chronic health issue which may be influenced by their gut microbiome²
- 2 years of research & development to bring the product to market
- Following the launch in Australia, expected to be rolled out through Microba's growing international distribution partner network.

¹ Sperber, Ami D., et al. (2021): 99-114. DOI: [10.1053/j.gastro.2020.04.014](https://doi.org/10.1053/j.gastro.2020.04.014)

² Estimated based on current literature on the understanding of the role of the microbiome in chronic disease (Vijay, Amrita, and Ana M. Valdes. (2022): 489-501. DOI: [10.1038/s41430-021-00991-6](https://doi.org/10.1038/s41430-021-00991-6)) and burden of these chronic diseases (Australian Bureau of Statistics (2020-21), [Health Conditions Prevalence](https://www.abs.gov.au/HealthConditionsPrevalence), ABS Website, accessed 20 March 2023.)

MetaXplore™ the most comprehensive GI testing solution available on market

25+

Markers for gastrointestinal and microbiome health.


100+

Clinical and research insights ranked by level of evidence using NHMRC guidelines.

28,000+


Microbial species profiled using Microba's world-leading microbiome profiling technology

Leading the clinical application of **microbiome testing** through comprehensive assessment of gastrointestinal and microbiome health to **advance the standard of care**



Partner distribution model

Scalable global testing services



Microba's leading international bench of healthcare partners



\$9.3bn Revenue
Partnership: UK, Germany, Belgium, Australia, US, NZ & Switzerland



\$5.8bn Revenue
Partnership: Europe & LATAM




Leading GI Diagnostics in US
Partnership: US



Raised USD \$800m
Partnership: GCC Region

Microba's **Healthcare & Pathology Partners**

Significant international distribution expansion for Microba's testing services




Access into **35 countries**

Operations **activated in 8 of 35 countries**

Significant growth prospects ahead

Accelerating expansion and adoption



Leading bench of healthcare partners provides access into **35 countries**

Staged rollout being executed to ensure market success

New regions to operationalise in FY23 are in focus.

Sonic expected to impact revenue from FY24

Microbiome Therapeutics

Developing novel monoclonal
microbial cell therapies

A therapeutic revolution.

Novel, precision microbiome therapeutics

Precision Microbiome Therapeutics

- Precision microbiome analysis platform delivering unparalleled accuracy, coverage & depth.
- Data driven discovery platform utilising one of the worlds **most advanced & highly curated microbiome datasets.**
- Next generation approach to microbiome drug development **identifying single keystone species and their biology to develop Live Biotherapeutics.**



Innovative Pipeline

- ✓ Excellent safety profile
- ✓ Scalable GMP manufacturing for high dose oral delivery
- ✓ Potent and novel biology mediated by Live Biotherapeutic strategy

Strong Corporate Profile

- ✓ US Pharmaceutical Executive leadership
- ✓ Technically robust multi-disciplinary team
- ✓ Global partners


Microba Partners



Team Experience



Repeatable, scalable, data-driven platform **discovering novel monoclonal microbial cell therapies**



Proprietary microbiome databank driving **multiple therapeutic opportunities through a capital light platform**

Rapid progress tapping the therapeutic potential of the human microbiome for major chronic diseases

Inflammatory Bowel Disease



PROGRESSING TO PHASE I

Recently Completed

- ✓ Manufacturing scale up
- ✓ FDA Pre-IND meeting requested
- ✓ FDA Pre-IND meeting outcome
- ✓ Phase 1 HREC submission

Upcoming milestones

- Phase 1 HREC approval
- cGMP manufacturing complete
- Phase 1 trial commencement



Cancer Immunotherapy



PRECLINICAL

Recently Completed

- ✓ Leads discovered
- ✓ Leads isolated
- ✓ First animal model results

Upcoming milestones

- Immunological MOA studies



Autoimmune Diseases



SCREENING

Recently Completed

- ✓ Program commenced
- ✓ Strains provided to Ginkgo

Upcoming milestones


- First in vitro screening results




Inflammatory Bowel Disease program – MAP 315

Addressing a key gap in existing therapy for UC sufferers


Ulcerative Colitis Addressable Patient Population¹



Ulcerative Colitis Therapeutic Global Market Size²



MAP 315 has the potential to provide **novel, potent therapeutic benefit** to UC patients through addressing a **key gap** in existing care – **epithelial and mucosal healing**



- More than 7 million patients worldwide live with IBD, and the incidence is increasing each year³
- Currently treated with anti-inflammatory and immunomodulatory medication to dampen the disease and control symptoms, with significant side effects
- Existing therapeutics fail to adequately address epithelial and mucosal healing with >50% of patients unable to achieve sustained remission¹, which frequently leads to surgical intervention⁴
- MAP 315 stimulates epithelial and mucosal healing⁵, a key unmet and novel treatment paradigm for patients living with this debilitating disease

¹ <https://www.crohnscolitisfoundation.org/sites/default/files/2019-02/Updated%20IBD%20Factbook.pdf>

² <https://www.nature.com/articles/d41573-021-00194-5> , <https://www.alliedmarketresearch.com/ulcerative-colitis-market>

³ [https://www.thelancet.com/journals/langas/article/PIIS2468-1253\(19\)30333-4/fulltext](https://www.thelancet.com/journals/langas/article/PIIS2468-1253(19)30333-4/fulltext)

⁴ <https://www.karger.com/Article/Fulltext/458006>

⁵ results from preclinical animal models, data on file

Inflammatory Bowel Disease program – MAP 315

Progressing into a first in human clinical trial



MANUFACTURING THROUGH TO DRUG PRODUCT

MAP 315 engineering production through to full encapsulated drug product.



Image: MAP 315 capsules at Bacthera



FDA PRE-IND MEETING POSITIVE OUTCOME


- Positive formal feedback from the FDA on Pre-IND briefing book and pre-clinical package.
- Supports upcoming HREC submission for Phase 1 study initiation.
- Supports roadmap to a global Phase II study for MAP 315.



Positive first animal data for Cancer Program

Positive animal efficacy data has been generated for Microba's immunology therapeutic leads.

A significant reduction in tumour size was observed in combination with immune checkpoint inhibitor (ICI) treatment in a mouse model of melanoma.



The global ICI market is valued at over \$30B¹ – a novel therapeutic that increases response to these drugs represents a substantial commercial opportunity

The start of a therapeutic revolution



APPROVED 30 Nov 2022
Faecal donor derived enema
drug product



**26 April PDUFA date for
anticipated FDA approval**
Faecal donor derived oral
capsule drug product



**RECENT FDA APPROVAL HAS
CLEARED THE PATH TO MARKET
FOR LIVE MICROBIOME DRUGS,
A NEW MODALITY.**

First Generation
Faecal Donor Derived



Second Generation
Bacterial Consortia



Next Generation
Single Strain & Small Molecule



Outlook



Upcoming Milestones for FY23

2023 JAN - MAR	2023 APR - JUN
<p>Services New healthcare product full launch </p>	
<p>Services New international distribution deals </p>	
<p>Therapeutics - IBD MAP315 program Phase 1 HREC Submission </p>	
<p>Therapeutics - IBD MAP315 program FDA Pre-IND meeting outcome </p>	
<p>Therapeutics - IO Program Pre-clinical results </p>	
<p>Therapeutics – Autoimmune Program First <i>in vitro</i> screening results</p>	
	<p>Services New international distribution deals</p>
	<p>Therapeutics - IBD MAP315 program GMP manufacture complete for Ph1</p>
	<p>Therapeutics - IBD MAP315 program HREC Approval for Phase 1 trial</p>
	<p>Therapeutics - IBD MAP315 program Phase 1 trial commencement</p>

Contact



Dr Luke Reid

Chief Executive Officer
luke.reid@microba.com



Pasquale Rombola

Chairman
pasquale.rombola@microba.com

Head Office

Level 10, 324 Queen Street
Brisbane QLD Australia

Laboratory

Princess Alexandra Hospital
Woolloongabba QLD Australia